Limits...
Effect of neoadjuvant chemotherapy on the serum levels of bone turnover markers in women with early-stage breast cancer.

Chen Y, Xu G, Yang F - PLoS ONE (2015)

Bottom Line: To evaluate effects of neoadjuvant chemotherapy on the bone turnover markers of preoperational breast cancer patients.Serum levels of the bone formation markers PINP and BAP, as well as the resorption markers ICTP and β-Crosslaps in addition to E2, FSH, 25(OH)D and PTH were measured at the initial diagnosis and at 24 hours after each four chemotherapy cycles.Patients with pronounced ICTP and β-Crosslaps combined with reduced BAP and PINP serum concentrations after neoadjuvant chemotherapies were prone to develop osteoporosis 6 month later.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Laboratory, Peking University Cancer Hospital and Institute, Beijing, China.

ABSTRACT

Background: To evaluate effects of neoadjuvant chemotherapy on the bone turnover markers of preoperational breast cancer patients.

Methods: Forty-one breast cancer patients (29 premenopausal and 12 postmenopausal) and 60 healthy women (30 premenopausal and 30 postmenopausal) aged 30-64 years, were evaluated for their bone status. Serum levels of the bone formation markers PINP and BAP, as well as the resorption markers ICTP and β-Crosslaps in addition to E2, FSH, 25(OH)D and PTH were measured at the initial diagnosis and at 24 hours after each four chemotherapy cycles. BMD T-scores were determined in 12 patients 6 months after the neoadjuvant chemotherapies.

Results: The baseline levels of both bone formation and resorption markers in premenopausal patients were higher than in premenopausal healthy women (p<0.05), while no statistic difference was observed between postmenopausal patients and postmenopausal healthy women. Regardless of the menopausal status, chemotherapy increased the ICTP and β-Crosslaps levels (p<0.05), but decreased the BAP and PINP levels (p<0.05), the later one significantly more with Taxane medication (p<0.01, p<0.05). Chemotherapy caused significant decreases of 25(OH)D levels in premenopausal (p<0.01) and postmenopausal (p<0.05) patients, however, did not affect the PTH concentrations. In premenopausal patients the E2 level decreased, while the FSH level increased after chemotherapy (p<0.05). Patients with pronounced ICTP and β-Crosslaps combined with reduced BAP and PINP serum concentrations after neoadjuvant chemotherapies were prone to develop osteoporosis 6 month later.

Conclusions: Neoadjuvant chemotherapy appeared to promote bone resorption and inhibit bone formation in both postmenopausal and premenopausal early-stage breast patients.

No MeSH data available.


Related in: MedlinePlus

Changes of serum bone turnover markers levels under different cycles of chemotherapy in post-menopausal breast cancers.(*) p< 0.05; (**) p<0.01. C0: the day of initial diagnosis; C1–C4: 24 hours after the first, second, third. Fourth cycle of chemotherapy.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4414610&req=5

pone.0126053.g002: Changes of serum bone turnover markers levels under different cycles of chemotherapy in post-menopausal breast cancers.(*) p< 0.05; (**) p<0.01. C0: the day of initial diagnosis; C1–C4: 24 hours after the first, second, third. Fourth cycle of chemotherapy.

Mentions: The serum BTMs In postmenopausal patients either at the C0 baseline levels or at the C4 post-chemotherapy levels showed no significant difference as compared to those in healthy postmenopausal women (Table 2). A comparison between the baseline levels and the levels during 4 cycles of neoadjuvant chemotherapy demonstrated that bone resorption markers, ICTP and β-Crosslaps significantly increased from 2.95 μg/L to 3.8 μg/L (p<0.05) and from 0.410 ng/mL to 0.540 ng/mL (p<0.05), respectively, while bone formation markers, BAP and PINP decreased from 17 μg g/L to 13.94 μg g/L (p<0.05) and from 63 ng/mL to 47.75 ng/mL (p<0.05), respectively (Fig 2). This pattern of increase and decrease in postmenopausal patients were similar to what was observed in premenopausal patients.


Effect of neoadjuvant chemotherapy on the serum levels of bone turnover markers in women with early-stage breast cancer.

Chen Y, Xu G, Yang F - PLoS ONE (2015)

Changes of serum bone turnover markers levels under different cycles of chemotherapy in post-menopausal breast cancers.(*) p< 0.05; (**) p<0.01. C0: the day of initial diagnosis; C1–C4: 24 hours after the first, second, third. Fourth cycle of chemotherapy.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4414610&req=5

pone.0126053.g002: Changes of serum bone turnover markers levels under different cycles of chemotherapy in post-menopausal breast cancers.(*) p< 0.05; (**) p<0.01. C0: the day of initial diagnosis; C1–C4: 24 hours after the first, second, third. Fourth cycle of chemotherapy.
Mentions: The serum BTMs In postmenopausal patients either at the C0 baseline levels or at the C4 post-chemotherapy levels showed no significant difference as compared to those in healthy postmenopausal women (Table 2). A comparison between the baseline levels and the levels during 4 cycles of neoadjuvant chemotherapy demonstrated that bone resorption markers, ICTP and β-Crosslaps significantly increased from 2.95 μg/L to 3.8 μg/L (p<0.05) and from 0.410 ng/mL to 0.540 ng/mL (p<0.05), respectively, while bone formation markers, BAP and PINP decreased from 17 μg g/L to 13.94 μg g/L (p<0.05) and from 63 ng/mL to 47.75 ng/mL (p<0.05), respectively (Fig 2). This pattern of increase and decrease in postmenopausal patients were similar to what was observed in premenopausal patients.

Bottom Line: To evaluate effects of neoadjuvant chemotherapy on the bone turnover markers of preoperational breast cancer patients.Serum levels of the bone formation markers PINP and BAP, as well as the resorption markers ICTP and β-Crosslaps in addition to E2, FSH, 25(OH)D and PTH were measured at the initial diagnosis and at 24 hours after each four chemotherapy cycles.Patients with pronounced ICTP and β-Crosslaps combined with reduced BAP and PINP serum concentrations after neoadjuvant chemotherapies were prone to develop osteoporosis 6 month later.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Laboratory, Peking University Cancer Hospital and Institute, Beijing, China.

ABSTRACT

Background: To evaluate effects of neoadjuvant chemotherapy on the bone turnover markers of preoperational breast cancer patients.

Methods: Forty-one breast cancer patients (29 premenopausal and 12 postmenopausal) and 60 healthy women (30 premenopausal and 30 postmenopausal) aged 30-64 years, were evaluated for their bone status. Serum levels of the bone formation markers PINP and BAP, as well as the resorption markers ICTP and β-Crosslaps in addition to E2, FSH, 25(OH)D and PTH were measured at the initial diagnosis and at 24 hours after each four chemotherapy cycles. BMD T-scores were determined in 12 patients 6 months after the neoadjuvant chemotherapies.

Results: The baseline levels of both bone formation and resorption markers in premenopausal patients were higher than in premenopausal healthy women (p<0.05), while no statistic difference was observed between postmenopausal patients and postmenopausal healthy women. Regardless of the menopausal status, chemotherapy increased the ICTP and β-Crosslaps levels (p<0.05), but decreased the BAP and PINP levels (p<0.05), the later one significantly more with Taxane medication (p<0.01, p<0.05). Chemotherapy caused significant decreases of 25(OH)D levels in premenopausal (p<0.01) and postmenopausal (p<0.05) patients, however, did not affect the PTH concentrations. In premenopausal patients the E2 level decreased, while the FSH level increased after chemotherapy (p<0.05). Patients with pronounced ICTP and β-Crosslaps combined with reduced BAP and PINP serum concentrations after neoadjuvant chemotherapies were prone to develop osteoporosis 6 month later.

Conclusions: Neoadjuvant chemotherapy appeared to promote bone resorption and inhibit bone formation in both postmenopausal and premenopausal early-stage breast patients.

No MeSH data available.


Related in: MedlinePlus